Loading
Cancer Genomics and Diagnostics · Journal article
Frontiers in Medicine · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a conceptual mini-review proposing a hypothesis-generating framework for integrating ctDNA and immune biomarker testing to distinguish biologically different molecular residual disease states and improve risk assessment. The authors acknowledge that prospective validation and clinical utility trials are required before implementation, and identify multiple methodological and standardization barriers that must be resolved.
Journal article. Patients across solid tumors (colorectal, lung, urothelial, breast, and melanoma) with molecular residual disease.
ctDNA interpretation is influenced by tumor burden, shedding, anatomic site, treatment-related cell death, sampling time, and analytical sensitivity Immune biomarkers provide complementary information on whether residual disease is recognized, contained, or permitted to escape by the host immune system Joint interpretation of ctDNA and immune assays may distinguish biologically different MRD states and improve longitudinal risk assessment if prospectively validated
Review acknowledges that standardization of preanalytics, assay limits, and immune harmonization is not yet established Clinical implementation requires standardized preanalytics, explicit assay limits, paired leukocyte controls, serial sampling, harmonized immune assays, and prospective trials
This framework is currently for hypothesis generation and research design; clinicians should not implement the proposed integrated approach in routine practice until prospective trials demonstrate clinical utility beyond prognostic association alone.
A conceptual review proposing an integrative framework for ctDNA and immune biomarkers in MRD surveillance, without new primary data or prospective validation of the proposed model.
This framework is currently for hypothesis generation and research design; clinicians should not implement the proposed integrated approach in routine practice until prospective trials demonstrate clinical utility beyond prognostic association alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Molecular residual disease (MRD) refers to occult cancer persisting below the detection limit of conventional imaging and is a major source of later relapse. Circulating tumor DNA (ctDNA) provides a minimally invasive molecular surrogate of residual disease, but its interpretation is influenced by tumor burden, shedding, anatomic site, treatment-related cell death, sampling time, and analytical sensitivity. Immune biomarkers provide complementary information on whether residual disease is being recognized, contained, or permitted to escape by the host immune system. This Mini Review examines how ctDNA and immune biomarker testing can be integrated for MRD surveillance and immune stratification across solid tumors. We summarize tumor-informed and tumor-naïve ctDNA approaches, including mutation-, methylation-, fragmentomic-, and whole-genome-based assays; discuss tissue and blood immune biomarkers such as PD-L1, mismatch repair status, tumor mutational burden, antigen-presentation integrity, T-cell receptor repertoires, cytokines, and suppressive myeloid populations; and review recent evidence from colorectal, lung, urothelial, breast, and melanoma studies. We propose a conceptual, hypothesis-generating framework in which ctDNA reports tumor-derived molecular signal and shedding, whereas immune assays report immune pressure and escape. Joint interpretation may, if prospectively validated, distinguish biologically different MRD states, improve longitudinal risk assessment, and provide a laboratory foundation for biomarker-oriented immunotherapy and cell-therapy studies. However, clinical implementation requires standardized preanalytics, explicit assay limits, paired leukocyte controls, serial sampling, harmonized immune assays, and prospective trials demonstrating clinical utility rather than prognostic association alone.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.